Vertex deal

VRTX (Cambridge, Mass.) entered into a clinical development program with BASF's Ravizza Farmaceutici S.p.A (Italy) subsidiary for compounds to treat inherited hemoglobin disorders.

The companies initially will share data generated in their respective clinical trial programs. VRTX is conducting U.S. and Canadian Phase II trials with VX-105, an injectable compound, for treatment of beta thalassemia and sickle cell anemia. VRTX recently completed a Phase I trial of VX-366, an orally available product candidate. ...